Advertisement
09/21/2022

Hikma intros 2 injectables

The company is offering bortezomib for injection 3.5 mg and ulvestrant injection 250 mg/5 ml.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Hikma is offering two new injectable products.

Bortezomib for injection 3.5 mg is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

[Read more: Hikma to acquire Custopharm]

Bortezomib injection had a market value of approximately $1 billion for the 12 months ending June 2022, according to IQVIA.

Hikma also launched fulvestrant injection 250 mg/5 ml.

The drug is indicated for the treatment of hormone-receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer in postmenopausal women.

[Read more: Hikma intros Kloxxado]

Fulvestrant injection had a market value of approximately $105 million in the 12 months ending June 2022, according to IQVIA.

    Advertisement
    Advertisement